ClinicalTrials.gg
CompletedNCT05168501Updated Jul 15, 2024Results posted

Assessing Variability of the Ventilatory Response to Duffin's Rebreathing Procedure

An interventional study of Rebreathing procedure in Ventilation, Reproducibility and Physiology, sponsored by Food and Drug Administration (FDA). Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Food and Drug Administration (FDA) · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study will combine Duffin's rebreathing procedure with additional study procedures, such as quantitative pupillometry, that are planned for subsequent clinical studies in order to confirm feasibility and gather reproducibility data using the procedure. The reproducibility of Duffin rebreathing has been assessed previously by Mahamed and Duffin (2001) performing hyperoxic and hypoxic rebreathing procedures measured once daily for 14 consecutive days and then by Jensen et al. (2010) performing 4 pairs of hyperoxic and hypoxic rebreathing procedures in 1 day followed by 1 pair on 4 additional days separated by weeks to more than a month.

The present study is an unblinded reproducibility assessment to assess variability of the ventilatory response to Duffin's rebreathing procedure. Subjects will report to the study site for screening between Days -28 to -2 and then will return to the site on Day -1 for baseline assessments and check-in. After check-in (Day -1), subjects will remain in study site for PD assessments on Day 1 and check out on Day 2.

Paired rebreathing procedures (i.e., at two different isoxic end tidal PO2 [partial pressure oxygen] levels) will be performed on Day 1 at 0, 2, 4, and 6 hours. An additional pair of rebreathing procedures will be performed on Day 2 before checkout (approximately 24 hours). Subjects will not be administered any drugs in this study.

02

Conditions studied

  • Ventilation
  • Reproducibility
  • Physiology

Keywords

  • Duffin's rebreathing procedure
  • Ventilation
  • Pupillometry
  • Physiology
03

In context

Lead sponsor

Food and Drug Administration (FDA) is the lead sponsor of 25 studies on the registry; 2 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 13 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject signs an Institutional Review Board (IRB)-approved written and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization) before any study related procedures are performed.
  2. Subject is a healthy, non-smoking man or woman, 18 to 50 years of age, inclusive, who has a of 18.5 to 32 kg/m2, inclusive, at Screening.
  3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead results, and physical examination findings at screening or, if abnormal, the abnormality is not considered (as determined and documented by the investigator or designee).
  4. Subject must have a negative test result for alcohol and drugs of abuse at screening and Check-in (Day -1).
  5. Subject must test negative for severe acute respiratory syndrome coronavirus (SARS-CoV-2) by a molecular diagnostic test at check-in (Day -1). If a subject's test comes back inconclusive, it can be repeated at Check-in.
  6. Female subjects must be of non- or, if they are of childbearing potential, they must: 1) have been strictly abstinent for 1 month before Check in (Day -1) and agree to remain strictly abstinent for the duration of the study and for at least 1-month after the last rebreathing procedure; OR 2) be practicing 2 highly effective methods of (as determined by the investigator or designee; one of the methods must be a barrier technique) from at least 1 month before Check in (Day -1) until at least 1 month after the end of the study.
  7. Male subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee) from at least 1 month before Check In (Day -1) until at least 1 month after the last rebreathing procedure.
  8. Subject is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject has non-reactive or misshapen pupil(s) or damaged orbit structure or surrounding soft tissue is edematous or has an open lesion.
  2. Subject Duffin rebreathing data is of poor quality or subject does not agree to remain clean-shaven for all days when the Duffin rebreathing procedure is being performed.
  3. Subject has used any prescription or nonprescription drugs (including aspirin or NSAIDs and excluding oral and acetaminophen) within 14 days or 5 half-lives (whichever is longer) or complementary and alternative medicines within 28 days before check-in.
  4. Subject has used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff) within 6 weeks of Screening
  5. Subject has a history or evidence of a disorder, condition, or disease (e.g., cancer, [HIV], hepatic or renal impairment) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. This includes subjects with any underlying medical conditions that the Investigator believes would put subjects at increased risk of severe illness from COVID-19 based on the Centers for Disease Control and Prevention (CDC) guidelines.
  6. Subject has any signs or symptoms that are consistent with COVID-19. These include subjects with fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea may have COVID-19. In addition, the subject has any other findings suggestive of COVID-19 risk in the opinion of the investigator.
  7. Subject tests positive for SARS-CoV-2 by a molecular diagnostic test performed prior to admission.
  8. Subject has clinical laboratory test results (hematology, serum chemistry and urinalysis) at Screening or Check-In that are outside the reference ranges provided by the clinical laboratory and considered clinically significant by the investigator.
  9. Subject has a positive test result at Screening for HIV 1 or 2 antibody, virus antibodies, or surface antigen.
  10. Female subject is pregnant or lactating before enrollment in the study.
  11. Subject has a history of or currently has hypoventilation syndrome, sleep apnea, or (COPD) and is on non-invasive ventilation.
  12. Subject has a history of asthma that has required medication within the last five years.
  13. Subject has a history of sleep disorders, Panic Disorder, Panic Attacks, Generalized Anxiety Disorder, or any associated DSM diagnosis or condition.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Lead-In

    Multiple rebreathing procedures using methodology developed by Duffin (referred to as Duffin's rebreathing procedure) will be conducted under hyperoxic and hypoxic conditions over the course of a day to confirm feasibility and gather reproducibility data using the procedure.

    Other: Rebreathing procedure

Interventions

  • OtherRebreathing procedure

    Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.

06

What researchers measure

Primary outcomes

  1. Baseline Minute Ventilation

    Minute ventilation during the rebreathing assessment when end tidal PCO2 (partial pressure carbon dioxide) is less than the ventilatory recruitment threshold (represents non-chemoreflex drives to breathe; 'flat' portion of minute ventilation versus end tidal PCO2 relationship). Data was analyzed using linear-mixed effects regression of baseline minute ventilation with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

    Time frame: 0, 2, 4, 6 and 24 hours

  2. Ventilatory Recruitment Threshold

    The end tidal PCO2 point above which minute ventilation starts to increase linearly with further increases in end tidal PCO2. Data was analyzed using linear-mixed effects regression of ventilatory recruitment threshold with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

    Time frame: 0, 2, 4, 6 and 24 hours

  3. Slope of the PCO2-ventilatory Response Curve

    Slope of the minute ventilation versus end tidal PCO2 curve that reflects the increase in minute ventilation relative to the increase in end tidal PCO2. Data was analyzed using linear-mixed effects regression of Slope of the PCO2-ventilatory response curve with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

    Time frame: 0, 2, 4, 6 and 24 hours

  4. Extrapolated Ventilatory Recruitment Threshold

    Intersection of the slope of the PCO2-ventilation response curve with the X axis. Data was analyzed using linear-mixed effects regression of extrapolated ventilatory recruitment threshold with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

    Time frame: 0, 2, 4, 6 and 24 hours

07

Results

Posted Jul 15, 2024

Participant flow

Enrollment was halted after 7 participants as sufficient experience with the experimental technique was obtained to move on to subsequent studies.

Participant flow — Overall Study
MilestoneLead-In
Started7
Completed7
Not completed0

Outcome measures

PrimaryBaseline Minute Ventilation

Minute ventilation during the rebreathing assessment when end tidal PCO2 (partial pressure carbon dioxide) is less than the ventilatory recruitment threshold (represents non-chemoreflex drives to breathe; 'flat' portion of minute ventilation versus end tidal PCO2 relationship). Data was analyzed using linear-mixed effects regression of baseline minute ventilation with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

Time frame:
0, 2, 4, 6 and 24 hours
Reported as:
Mean · L/min
Baseline Minute Ventilation
L/minHyperoxic RebreathingHypoxic Rebreathing
Baseline Minute Ventilation11.6 ± 3.412.0 ± 2.9
PrimaryVentilatory Recruitment Threshold

The end tidal PCO2 point above which minute ventilation starts to increase linearly with further increases in end tidal PCO2. Data was analyzed using linear-mixed effects regression of ventilatory recruitment threshold with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

Time frame:
0, 2, 4, 6 and 24 hours
Reported as:
Mean · mmHg
Ventilatory Recruitment Threshold
mmHgHyperoxic RebreathingHypoxic Rebreathing
Ventilatory Recruitment Threshold43.0 ± 3.038.1 ± 1.7
PrimarySlope of the PCO2-ventilatory Response Curve

Slope of the minute ventilation versus end tidal PCO2 curve that reflects the increase in minute ventilation relative to the increase in end tidal PCO2. Data was analyzed using linear-mixed effects regression of Slope of the PCO2-ventilatory response curve with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

Time frame:
0, 2, 4, 6 and 24 hours
Reported as:
Mean · L/min/mmHg
Slope of the PCO2-ventilatory Response Curve
L/min/mmHgHyperoxic RebreathingHypoxic Rebreathing
Slope of the PCO2-ventilatory Response Curve3.19 ± 2.463.28 ± 2.41
PrimaryExtrapolated Ventilatory Recruitment Threshold

Intersection of the slope of the PCO2-ventilation response curve with the X axis. Data was analyzed using linear-mixed effects regression of extrapolated ventilatory recruitment threshold with random effects for between subject, between day, and between occasion variability. Reported value is the mean for the treatment group across all individuals, days, and times.

Time frame:
0, 2, 4, 6 and 24 hours
Reported as:
Mean · mmHg
Extrapolated Ventilatory Recruitment Threshold
mmHgHyperoxic RebreathingHypoxic Rebreathing
Extrapolated Ventilatory Recruitment Threshold36.8 ± 7.132.7 ± 5.9

Adverse events

Collected over 2 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hyperoxic Rebreathing0/7 (0%)0/7 (0%)0/7 (0%)
Hypoxic Rebreathing0/7 (0%)0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lead-In
Mean30.6 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Lead-In
Female2
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lead-In
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White5
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Lead-In
United States7
08

Study locations

1 site
  • Spaulding Clinical Research
    West Bend, Wisconsin 53095, United States
09

References and documents

Publications

  • Duffin J. Measuring the respiratory chemoreflexes in humans. Respir Physiol Neurobiol. 2011 Jul 31;177(2):71-9. doi: 10.1016/j.resp.2011.04.009. Epub 2011 Apr 14. PubMed 21514404 ↗
  • Mahamed S, Duffin J. Repeated hypoxic exposures change respiratory chemoreflex control in humans. J Physiol. 2001 Jul 15;534(Pt. 2):595-603. doi: 10.1111/j.1469-7793.2001.00595.x. PubMed 11454975 ↗
  • Jensen D, Mask G, Tschakovsky ME. Variability of the ventilatory response to Duffin's modified hyperoxic and hypoxic rebreathing procedure in healthy awake humans. Respir Physiol Neurobiol. 2010 Feb 28;170(2):185-97. doi: 10.1016/j.resp.2009.12.007. Epub 2009 Dec 24. PubMed 20035904 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Feb 2022, 1 month.

Results were first posted in Jul 2024, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Dec 23, 2021
StartActual
Dec 27, 2021
Primary completionActual
Feb 18, 2022
CompletionActual
Feb 18, 2022
Results first posted
Jul 15, 2024
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05168501
Lead sponsor
Food and Drug Administration (FDA)
Collaborators
Spaulding Clinical Research LLC
Responsible party
Sponsor
First posted
Dec 23, 2021
Start date
Dec 27, 2021
Primary completion
Feb 18, 2022
Completion
Feb 18, 2022
Results posted
Jul 15, 2024
Last update
Jul 15, 2024

Study contacts

Jan Matousek, D.O.
principal investigator · Spaulding Clinical Research LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion